trending Market Intelligence /marketintelligence/en/news-insights/trending/d6Bn-fnGF5KDFWQFxGVLkA2 content esgSubNav
In This List

Acorda to appeal ruling invalidating multiple sclerosis drug patents

Blog

Commercial Banking: June 22nd Edition

Blog

Understanding Loss Given Default A Review of Three Approaches

Blog

Insight Weekly: Path to net-zero; US manufacturing momentum; China's lithium M&A frenzy

Blog

Commercial Banking Newsletter June Edition - 2022


Acorda to appeal ruling invalidating multiple sclerosis drug patents

Acorda Therapeutics Inc. plans to appeal the U.S. District Court of Delaware ruling that invalidated four U.S. patents related to its multiple sclerosis drug AMPYRA.

The court, meanwhile, upheld a patent related to the drug, which is set to expire in July 2018.

The U.S. Patent and Trademark Office had previously upheld these four patents which were challenged via the inter partes review process.